Overview
Informuta develops precision diagnostics for drug-resistant infections using machine learning and DNA sequencing technology. The company's RESISENSE platform forecasts treatment-emergent antibiotic resistance before it occurs, enabling clinicians to select optimal therapies on a patient-by-patient basis. Informuta's technology helps prevent treatment failures, reduce antibiotic misuse, and strengthen antimicrobial stewardship in hospital settings.
Frequently asked questions
- What is Informuta's core diagnostic technology?
- Informuta's RESISENSE platform combines AI and DNA sequencing to analyze bacterial infections for current antibiotic susceptibilities and predict the likelihood of resistance development during treatment. The technology can forecast resistance probability at specific timepoints (7, 30, 90 days) to guide clinical decision-making.
- What regulatory certifications is Informuta pursuing?
- Informuta is working toward Clinical Laboratory Improvement Amendments (CLIA) certification for its clinical laboratory at the New Orleans BioInnovation Center, which will enable validated diagnostic reporting for direct patient care impact.
- Which bacterial pathogens does Informuta's technology address?
- While initial research focused on Pseudomonas aeruginosa (a CDC-designated serious resistance threat), Informuta's technology is broadly applicable to virtually all medically important and difficult-to-treat bacteria.
- What is Informuta's implementation timeline for clinical use?
- Informuta is targeting its first full implementation pilot by the end of 2026, with plans for 24-hour turnaround results integrated into real-time treatment protocols, initially through partnership with Ochsner Health.
- How does Informuta's approach differ from traditional diagnostics?
- Traditional diagnostics provide a snapshot of current drug susceptibility. Informuta adds predictive capability by forecasting how bacterial resistance will evolve over the course of treatment, enabling proactive therapeutic selection rather than reactive adjustments.